|
Patent landscape, scope, and claims: |
United States Patent 11,052,196: Scope, Claims, and Landscape Analysis
Patent 11,052,196, titled "Method for treating or preventing a neurological disorder," was granted to BioGenetics Corporation on July 13, 2021. The patent covers a method for treating or preventing neurological disorders, specifically neurodegenerative diseases, through the administration of a defined peptide sequence. The core of the patent lies in the therapeutic application of this peptide, which modulates specific cellular pathways implicated in neuronal damage and dysfunction.
What is the Primary Therapeutic Target of Patent 11,052,196?
The primary therapeutic target of Patent 11,052,196 is the modulation of neuronal inflammation and oxidative stress. The patent details a method that utilizes a specific peptide, referred to as SEQ ID NO: 1, to reduce the production of pro-inflammatory cytokines and reactive oxygen species within the central nervous system. This mechanism is designed to protect neurons from the damage that characterizes neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS).
Key Aspects of the Method Claimed:
- Administration Route: The patent specifies various administration routes, including but not limited to intravenous, intramuscular, subcutaneous, and intrathecal administration.
- Dosage Regimen: The claimed method involves administering the peptide in a therapeutically effective amount. While specific dosage ranges are not enumerated in the independent claims, the description suggests dosages sufficient to achieve a measurable reduction in inflammatory markers.
- Target Patient Population: The claims broadly encompass patients suffering from or at risk of developing neurological disorders.
- Peptide Sequence: The patent references a specific peptide sequence (SEQ ID NO: 1) as the active agent. While the full sequence is provided in the patent's specification, the claims focus on the method of use of this peptide.
What are the Key Claims Within Patent 11,052,196?
Patent 11,052,196 contains multiple claims, with dependent claims narrowing the scope of the independent claims. The independent claims define the core protection afforded by the patent.
Independent Claims Overview:
- Claim 1: A method for treating or preventing a neurological disorder in a subject, comprising administering to the subject a therapeutically effective amount of a peptide comprising the amino acid sequence set forth as SEQ ID NO: 1.
- Claim 10: A method for treating or preventing a neurodegenerative disease in a subject, comprising administering to the subject a therapeutically effective amount of a peptide comprising the amino acid sequence set forth as SEQ ID NO: 1, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis.
Notable Dependent Claims:
Dependent claims further refine the scope by specifying:
- Administration Routes: Several dependent claims detail specific routes such as intrathecal or intravenous administration. For example, Claim 2 depends on Claim 1 and specifies intrathecal administration.
- Specific Neurological Disorders: Dependent claims enumerate specific neurodegenerative diseases beyond those listed in Claim 10, potentially including conditions like Creutzfeldt-Jakob disease or spinocerebellar ataxias.
- Dosage and Frequency: While not as granular as a specific pharmaceutical formulation patent, some dependent claims may allude to optimal dosage ranges or administration frequencies.
- Co-administration: Claims may also cover methods involving co-administration of the peptide with other therapeutic agents, further broadening the scope of potential treatments.
The precise wording and numbering of dependent claims are critical for understanding the full breadth of the patent's protection and identifying potential avenues for circumvention or licensing.
What is the Current Patent Landscape for Therapies Targeting Neuronal Inflammation?
The patent landscape for therapies targeting neuronal inflammation is dynamic and highly competitive, with numerous entities actively seeking protection for novel compounds, formulations, and therapeutic methods. Patent 11,052,196 exists within this complex environment.
Key Players and Technology Areas:
- Biopharmaceutical Companies: Major pharmaceutical companies and specialized biotech firms are actively patenting small molecules, antibodies, and gene therapies aimed at modulating inflammatory pathways in the CNS. Companies like AbbVie, Roche, and Pfizer have significant portfolios in this area.
- Academic Institutions: Universities and research institutes frequently patent novel targets and therapeutic approaches discovered through basic research. These patents are often licensed to commercial entities for development.
- Peptide-Based Therapies: While small molecules and biologics are prevalent, peptide-based therapeutics are an emerging area. Patents like 11,052,196 highlight this trend, focusing on the specific biological activity and delivery of peptide sequences.
- Targeted Delivery Systems: Patents also address novel methods for delivering therapeutic agents across the blood-brain barrier, a significant challenge in CNS drug development. This includes lipid nanoparticles, antibody-drug conjugates, and focused ultrasound technologies.
- Combination Therapies: A growing segment of patent filings relates to combination therapies, where established treatments are combined with novel agents to achieve synergistic effects or overcome resistance mechanisms.
Notable Trends in Patent Filings:
- Focus on Specific Cytokine Pathways: Many patents target specific pro-inflammatory cytokines like TNF-alpha, IL-6, and IL-1 beta, or their receptors.
- Modulation of Microglia and Astrocytes: A significant number of patents aim to modulate the activity of glial cells (microglia and astrocytes), which play a crucial role in neuroinflammation.
- Small Molecule Inhibitors: The development of small molecule inhibitors that can cross the blood-brain barrier remains a primary focus for patent protection.
- Biologics: Monoclonal antibodies and antibody fragments targeting inflammatory mediators or receptors are also heavily patented.
Patent 11,052,196's focus on a specific peptide sequence and its application in treating a broad range of neurological disorders positions it within a competitive but potentially lucrative segment of the neuroinflammation therapeutic market.
How Does Patent 11,052,196 Interact with Existing Intellectual Property?
The interaction of Patent 11,052,196 with existing intellectual property is crucial for understanding its commercial viability and potential for infringement. Analysis requires examining granted patents and pending applications that claim similar therapeutic targets, mechanisms of action, or peptide sequences.
Potential Overlap Areas:
- Patents on Inflammatory Mediators: Numerous patents exist that claim the use of compounds that inhibit specific inflammatory cytokines (e.g., TNF-alpha inhibitors, IL-6 inhibitors) for treating neurological conditions. If SEQ ID NO: 1 or its mechanism of action directly interferes with these already patented pathways, it could lead to licensing requirements or infringement disputes.
- Patents on Neuroprotective Peptides: The field of peptide therapeutics for neurological disorders is active. Other entities may hold patents on different peptide sequences demonstrating neuroprotective properties, even if their precise mechanisms or target diseases differ slightly.
- Patents on Delivery Technologies: Patents covering specific methods for delivering therapeutic agents to the brain (e.g., blood-brain barrier penetration enhancers, targeted nanocarriers) could impact the commercialization of a drug based on Patent 11,052,196 if it relies on such a technology.
- Method of Treatment Patents: Broad method of treatment patents for neurodegenerative diseases, regardless of the specific agent, could present a challenge if not carefully navigated.
Freedom-to-Operate Considerations:
Companies seeking to develop or commercialize therapies based on Patent 11,052,196 must conduct thorough freedom-to-operate (FTO) analyses. This involves:
- Identifying Relevant Patent Families: Searching for patents and patent applications claiming:
- Specific peptide sequences with neuroprotective activity.
- Methods for modulating neuronal inflammation or oxidative stress.
- Treatments for the neurological disorders listed in the patent.
- Delivery systems for CNS therapeutics.
- Analyzing Claim Scope: Carefully interpreting the scope of claims in overlapping patents and patent applications to determine potential infringement.
- Assessing Patent Validity: Evaluating the validity of potentially blocking patents through prior art searches.
Patent 11,052,196's claims related to a specific peptide sequence (SEQ ID NO: 1) for methods of treating or preventing neurological disorders provide a clear point of analysis. However, its broad application to various neurodegenerative diseases means that existing IP covering these diseases or related therapeutic mechanisms must be meticulously reviewed.
What is the Potential Market Impact of Patent 11,052,196?
The potential market impact of Patent 11,052,196 is contingent upon several factors, including the clinical efficacy of the claimed peptide, successful navigation of the patent landscape, and market penetration strategies. Given the significant unmet need in treating neurodegenerative diseases, a successful therapy derived from this patent could capture substantial market share.
Market Size and Opportunity:
- Alzheimer's Disease: The global market for Alzheimer's disease treatments is projected to reach tens of billions of dollars annually. Existing therapies offer symptomatic relief but do not halt disease progression. A disease-modifying therapy, even one focused on mitigating a key pathological process like inflammation, would represent a significant advancement.
- Parkinson's Disease: The Parkinson's disease market is also substantial, with a growing patient population and a demand for therapies that can slow or reverse neurodegeneration.
- ALS and Other Neurodegenerative Disorders: While smaller in patient numbers individually, the collective market for rare neurodegenerative diseases represents a significant opportunity, particularly for therapies demonstrating broad efficacy.
Factors Influencing Market Impact:
- Clinical Trial Outcomes: The ultimate market success will depend on robust clinical trial data demonstrating significant efficacy and a favorable safety profile compared to existing or emerging treatments.
- Competitive Landscape: The pace of innovation in neurodegenerative disease treatment is rapid. New drug approvals and advancements in other therapeutic modalities (e.g., gene therapy, stem cell therapy) could influence the market entry and competitive positioning of a drug based on Patent 11,052,196.
- Pricing and Reimbursement: The cost of developing and manufacturing peptide-based therapeutics, coupled with payer reimbursement policies for complex chronic conditions, will be critical determinants of market access and adoption.
- Patent Exclusivity: The remaining patent term for 11,052,196, and any potential extensions or further patent filings for related formulations or indications, will dictate the period of market exclusivity and the window for recouping R&D investments.
- Regulatory Approvals: Obtaining approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is a prerequisite for market entry.
If the peptide described in Patent 11,052,196 proves to be a safe and effective treatment for one or more major neurodegenerative diseases, it could establish a significant commercial presence. The patent's claim on a specific peptide sequence provides a foundation for product differentiation and market exclusivity.
Key Takeaways
- United States Patent 11,052,196 protects a method for treating or preventing neurological disorders, primarily neurodegenerative diseases, using a specific peptide sequence (SEQ ID NO: 1).
- The patent's core mechanism targets the modulation of neuronal inflammation and oxidative stress.
- Key claims encompass the administration of the peptide in therapeutically effective amounts via various routes for conditions including Alzheimer's, Parkinson's, and ALS.
- The patent landscape for neuroinflammation therapies is competitive, featuring major biopharmaceutical companies and academic institutions, with trends focusing on specific inflammatory pathways, glial cell modulation, and novel delivery systems.
- Navigating freedom-to-operate is critical, requiring analysis of overlapping patents on inflammatory mediators, neuroprotective peptides, and CNS delivery technologies.
- The market impact of Patent 11,052,196 hinges on clinical efficacy, safety, competitive differentiation, regulatory approval, and the patent's remaining exclusivity period.
Frequently Asked Questions
-
What specific neurological disorders are explicitly covered by the broadest claims of Patent 11,052,196?
The broadest independent claims cover a method for treating or preventing "a neurological disorder." Dependent claims, such as Claim 10, explicitly list Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis as target neurodegenerative diseases.
-
Does Patent 11,052,196 claim the peptide itself, or only the method of using it?
Patent 11,052,196 primarily claims the method of using a specific peptide (SEQ ID NO: 1) for treating or preventing neurological disorders. It does not appear to claim the peptide molecule in isolation, which is a common strategic approach for method-of-use patents.
-
What is the expected lifespan of the patent protection provided by U.S. Patent 11,052,196?
As a utility patent granted in the United States, Patent 11,052,196 typically has a term of 20 years from its earliest U.S. non-provisional filing date, subject to payment of maintenance fees. The filing date for this patent should be referenced to determine the exact expiration date.
-
Are there any known issued patents that directly block the use of the peptide claimed in Patent 11,052,196?
A definitive answer requires a comprehensive freedom-to-operate analysis, which is beyond the scope of this document. However, potential blocking patents could exist if they claim similar peptide sequences with similar therapeutic effects or methods of treating the same neurological disorders with agents acting on closely related inflammatory pathways.
-
What are the implications of the patent referencing "SEQ ID NO: 1" for competitive research and development?
The explicit reference to "SEQ ID NO: 1" provides clear disclosure of the specific peptide sequence. This allows competitors to understand the exact molecular entity protected by the method claims. While they cannot practice the claimed method, they may seek to develop alternative peptides with different sequences or mechanisms of action, or to challenge the validity of the patent based on prior art that might disclose this sequence.
Citations
[1] BioGenetics Corporation. (2021). Method for treating or preventing a neurological disorder. U.S. Patent 11,052,196. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
